ZAP Surgical Secures $36 Million Led by Catalio Capital Management to Scale Non-Invasive Brain Surgery
The Investment underscores ZAP's momentum in neuro-oncology and emerging neuropsychiatric applications
SAN CARLOS, Calif., October 19, 2026--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced it has secured $36 million in financing led by Catalio Capital Management, a leading innovative healthcare and AI investment firm, with continued support from Baheal, ZAP's strategic partner in China. The financing reflects strong investor confidence in ZAP's technology, commercial momentum, and growth potential for non-invasive robotic therapeutics throughout neuroscience.
The capital will support global expansion of the company's ZAP-X® Gyroscopic Radiosurgery® platform to healthcare institutions across leading academic medical centers, community hospitals, and physician led practices. ZAP recently achieved a major commercial milestone with the shipment of its 50th ZAP-X system and is currently scaling its production capacity to support increasing demand globally. With nearly 10,000 patients treated worldwide, the growing body of clinical evidence continues to demonstrate the advantages of Gyroscopic Radiosurgery in treatment precision and speed for brain tumors and other neurological conditions.
"This financing reflects our conviction that ZAP Surgical is uniquely positioned to usher in a new wave of non-invasive radiosurgery globally," said Catalio's Nicholas von Guionneau, M.D., Ph.D., who also joins ZAP's Board as an Observer. "With rising healthcare costs in developed nations and underserved populations in emerging markets, intelligent robotics will play an indispensable role in reducing cost structures while elevating the standard of care. ZAP's mission to make non-invasive brain therapy broadly accessible aligns perfectly with our strategy of backing disruptive healthcare technologies."
Beyond well-established indications in neuro-oncology, ZAP and collaborators have over the past decade demonstrated in multiple mammalian brain models the neuromodulatory effects of precisely targeted low dose ionizing radiation, now referred to as "radiomodulation." Preliminary data was recently reported from a first-in-human pilot study evaluating patients with severe treatment resistant depression (TRD) treated with radiomodulation on the ZAP-X platform. Based on encouraging early outcomes, broader multi-center clinical trials are now being planned to treat a wide variety of psychiatric disorders beginning with TRD and addiction.